Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers von Radovich, Milan, Kiel, Patrick J, Nance, Stacy M, Niland, Erin E, Parsley, Megan E, Ferguson, Meagan E, Jiang, Guanglong, Ammakkanavar, Natraj R, Einhorn, Lawrence H, Cheng, Liang, Nassiri, Mehdi, Davidson, Darrell D, Rushing, Daniel A, Loehrer, Patrick J, Pili, Roberto, Hanna, Nasser, Callaghan, J Thomas, Skaar, Todd C, Helft, Paul R, Shahda, Safi, O'Neil, Bert H, Schneider, Bryan P

Volltext

Adjuvant therapy for endometrial cancer von Deleon, Maria C, Ammakkanavar, Natraj R, Matei, Daniela

Volltext

Impact of dialysis requirement on outcomes in tumor lysis syndrome von Garimella, Pranav S., Balakrishnan, Poojitha, Ammakkanavar, Natraj R., Patel, Shanti, Patel, Achint, Konstantinidis, Ioannis, Annapureddy, Narender, Nadkarni, Girish N.

Volltext

Older Age and Co-Morbidities Do Not Predict Incidence of Dose Limiting Toxicities in Lymphoma Phase I Trials At MSKCC von Ammakkanavar, Natraj R, Leon, Chady Abboud, Hamlin, Paul

Volltext

Adjuvant therapy for endometrial cancer von Maria C Deleon, Natraj R Ammakkanavar, Daniela Matei

Volltext

Dose optimization of novel BRAF inhibitor FORE8394 based on PK and efficacy results von Sherman, Eric Jeffrey, De La Fuente, Macarena Ines, Yaeger, Rona, Tsai, Frank Yung-Chin, Janku, Filip, Butowski, Nicholas A., Allen, Carl E., Ammakkanavar, Natraj Reddy, Taylor, Jennie Webster, Samara, Emil, Mould, Diane R., Michelson, Glenn, Kline, Irina, Paz, Michael, Tussay-Lindenberg, Alexia, Wong, Kongming, Shepherd, Stacie Peacock, Jiang, Ping, Rodon Ahnert, Jordi

Volltext

Role of platinum-based chemotherapy for Merkel cell tumor in adjuvant and metastatic settings von Satpute, Shailesh R., Ammakkanavar, Natraj Reddy, Einhorn, Lawrence H.

Volltext

Feasibility of tumor genome sequencing: single center experience von Ammakkanavar, Natraj Reddy, Kiel, Patrick J., Niland, Erin, Ferguson, Meagan E, Nance, Stacy Marie, Radovich, Milan, Helft, Paul R., Schneider, Bryan P.

Volltext

Abstract CT028: A first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumors von Murciano-Goroff, Yonina R., Heist, Rebecca S., Kuboki, Yasutoshi, Koyama, Takafumi, Ammakkanavar, Natraj Reddy, Hollebecque, Antoine, Patnaik, Amita, Shimizu, Toshio, Spira, Alexander I., Nagasaka, Misako, Han, Ji-Youn, Iams, Wade Thomas, Deming, Dustin, Call, Justin, Cassier, Philippe, Han, Sae-Won, Siu-chung Chu, Quincy, Cosman, Rasha, Durm, Gregory, Burns, Timothy, Willard, Melinda D., Liu, Shiyao, Callies, Sophie, Balar, Arjun V., Sabari, Joshua K.

Volltext